Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label SEP-363856 in clinically stable schizophrenia
jRCT2071250092Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ulotaront in schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Treatment-emergent adverse events incidence. Started Dec 2025; status: recruiting.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2071250092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250092.